Home/Pipeline/IBD Subclassification

IBD Subclassification

Inflammatory Bowel Disease

ResearchActive

Key Facts

Indication

Inflammatory Bowel Disease

Phase

Research

Status

Active

Company

Bio-Me

About Bio-Me

Bio-Me is a commercial-stage microbiome analytics company based in Oslo, Norway. Its proprietary qPCR-based PMP™ platform addresses key limitations of next-generation sequencing (NGS) by offering faster turnaround, higher precision, lower cost, and simplified bioinformatics, making large-scale, routine microbiome analysis feasible. The company has successfully transitioned from a service provider to a diagnostics development partner, with active programs in women's health, oncology, and inflammatory diseases, supported by strategic partnerships with biotechs and participation in EU consortia. Leadership has recently been bolstered with a Co-CEO structure to drive capitalization and commercial growth.

View full company profile

Therapeutic Areas

Oncology Women's Health Gastroenterology Immunology

Other Inflammatory Bowel Disease Drugs

Drug	Company	Phase	Status
DVI-001	Divamics	Preclinical	Approaching PCC selection
DVI-002	Divamics	Preclinical	Lead optimization
Turq-101	Turquoise Biotechnologies	Preclinical	Active
GS-4875	Gilead	Phase 2	Active
Function-based Consortium for IBD	PharmaBiome	Pre-clinical	Active
Galapagos Collaboration	Scipher Medicine	Discovery/Pre-clinical	Active
Anti-iRhom2 antibodies	SciRhom	Pre-clinical	Active
IBD Multi-omics Dataset	Ovation.io	Commercial	Active
Noa‑001	Noa Therapeutics	Preclinical	Active
Inflectra	EMS	Phase 3	Active
IW-601	ImmuneWalk Therapeutics	Preclinical	Active
TRWR‑IBD	Taiwan Resonant Waves Research	Preclinical	Active